Novavax, Inc. (NVAX)
| Previous close | 221.50 |
| Open | 225.50 |
| Bid | 226.02 x 900 |
| Ask | 226.36 x 900 |
| Day's range | 217.87 - 233.30 |
| 52-week range | 6.77 - 331.68 |
| Volume | 1,015,876 |
| Avg. volume | 5,042,652 |
| Market cap | 15.366B |
| Beta (5Y monthly) | 1.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Johnson & Johnson vs. Novavax: Which Vaccine Is Best Against New Strains?
Johnson & Johnson and Novavax are approaching the finish line in this race. A U.S. Food and Drug Administration (FDA) committee meets today, Feb. 26, to discuss a possible Emergency Use Authorization (EUA) for the Johnson & Johnson candidate. A trial report released this week shows Johnson & Johnson's investigational vaccine fulfilled (and exceeded) efficacy and safety requirements.
- Motley Fool
Is Novavax Stock a Buy?
Novavax (NASDAQ: NVAX) is one stock that I made the right call on; it's been a huge winner. As far back as March 2018, I wrote that "if you're willing to take on risk, buying a small position in Novavax could pay off in a big way." Throughout 2020, I sang Novavax's praises.
- Motley Fool
Here Are the 2 Most Important Things to Look for in Novavax's Earnings Report Next Week
Novavax doesn't have products on the market yet, which means the biotech company is yet to report an annual profit. Novavax recently reported U.K. phase 3 trial results and just completed enrollment in a U.S. phase 3 trial. Possible regulatory authorizations sit on the horizon.
